· Published by Health Canada · Official notice
This is duplicated text of a letter from Janssen Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
July 28, 2014
To: Hospital Chief of Medical Staff
Please distribute to relevant Departments [Surgery, Emergency Medicine, Pharmacy, Anaesthesia, Geriatrics, Internal Medicine, Nursing, Neurology, Oncology, Rheumatology, Palliative Care, Pain Management, Intensive Care and/or other Departments as required], and other involved professional staff and post this notice in your institution.
Subject: DURAGESIC® MAT (fentanyl transdermal system) - Introduction of a Single Ink Colour (Dark Green) on all Strengths of Patches
Janssen Inc., in consultation with Health Canada, would like to inform you of the potential for dosing errors with changes to ink printing on the patches of DURAGESIC® MAT. Currently, different colours of ink in combination with the text on the patch are used to identify the different strengths of DURAGESIC® MAT (12, 25, 50, 75, and 100 mcg/h). Current users should be aware that one shade of dark green ink, intended to enhance visibility of the patch, will now be used on all strengths. The product carton and pouch will retain the use of the multi-colour system to aid in further differentiating the various patch strengths.
Graphics displaying the changes to the new dark green ink for the various patch strengths are provided below for your reference.
The first lots of DURAGESIC® MAT with one colour ink for all strengths are beginning to be shipped to wholesalers in late July.
Health Canada is working with Janssen Inc., the Market Authorization Holder for DURAGESIC® MAT, on revisions to the outer packaging to highlight the change to darker green ink printing on all strengths of the patch.
DURAGESIC® MAT is indicated in the management of persistent, moderate to severe chronic pain that cannot be managed by other means such as opioid combination products or immediate-release opioids.
Accidental exposure can occur by unintentional patch transfer to a non-patch wearer while hugging, sharing a bed or moving a patient. Accidental ingestion or use of patches can also occur from patches that have either fallen off or been inappropriately stored or discarded.
To reduce the risk of accidental exposure, information on the safe storage, handling, use and disposal of fentanyl patches is available on the Healthy Canadians Web site.
A patient information sheet is included in the package of DURAGESIC® MAT patches dispensed to the patient. Please refer to the DURAGESIC® MAT Product Monograph for full prescribing information. The current DURAGESIC® MAT Product Monograph can be found at the Janssen Canada Web site and Health Canada's Web page.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of dosing errors or other serious or unexpected adverse reactions in patients receiving DURAGESIC® MAT should be reported to Janssen Inc. or Health Canada. Medication errors can also be reported to the Institute for Safe Medication Practices (ISMP) Canada through the Canadian Medication Incident Reporting and Prevention System.
Drug Safety Department
Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
Or call toll free at 1-866-825-7122
Or email to dsscan@joica.jnj.com
Or fax to 1-866-767-5865
To correct your mailing address or fax number, contact Janssen Inc.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Should you have any questions or require additional information regarding the use of DURAGESIC® MAT, please contact Janssen Inc. Medical Information Department at 1-800-567-3331 or 1-800-387-8781 from 8:30 a.m. to 4:30 p.m. Monday to Friday Eastern Standard Time (EST). A copy of this letter is also available on the Janssen Web site and on the Health Canada Web site.
Sincerely,
original signed by
Cathy Lau, Ph.D.
Vice President
Regulatory Affairs and Quality Management
All trademarks used under license.
| Strength | Current Colour | New Colour |
|---|---|---|
| Duragesic 12 mcg/h (fentanyl transdermal) | light orange | dark green |
| Duragesic 25 mcg/h (fentanyl transdermal) | light pink | |
| Duragesic 50 mcg/h (fentanyl transdermal) | light green | |
| Duragesic 75 mcg/h (fentanyl transdermal) | light blue | |
| Duragesic 100 mcg/h (fentanyl transdermal) | light grey |